Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyse the changes of A/H premium on 140 stocks over the last week.</li>
<li>A-H premium increased by 1.8ppt last week, mainly led by health care, utilities, consumer discretionary sector.</li>
<li>We highlight A-H premium changes in Cansino, Great Wall Motor, Shandong Xinhua, Xinhua Winshare, First Tractor, Joinn Lab.</li>
</ul>


We analyse the changes of A/H premium on 140 stocks over the last week.
A-H premium increased by 1.8ppt last week, mainly led by health care, utilities, consumer discretionary sector.
We highlight A-H premium changes in Cansino, Great Wall Motor, Shandong Xinhua, Xinhua Winshare, First Tractor, Joinn Lab.


A-H Premium Weekly: Cansino, Great Wall Motor, Shandong Xinhua

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>Inside is a recap of movements in the last week relating to the Shanghai and Shenzhen-Hong Kong Stock Connect facilities, broken down by company and industry. </li>
<li>Overall, net inflow was ~US$1.1bn, split evenly (roughly) between Shanghai and Shenzhen. </li>
<li>The largest inflows were into  <a href="https://www.smartkarma.com/entities/china-mobile-ltd" target="_blank" data-smartkarma-citation="entities:27:1" rel="noopener">China Mobile (941 HK)</a> and <a href="https://www.smartkarma.com/entities/cnooc-ltd" target="_blank" data-smartkarma-citation="entities:175:1" rel="noopener">CNOOC Ltd (883 HK)</a>. The largest outflows were in <a href="https://www.smartkarma.com/entities/beijing-kuaishou-technology-co-ltd" target="_blank" data-smartkarma-citation="entities:29725:1" rel="noopener">Kuaishou Technology (1024 HK)</a> and <a href="https://www.smartkarma.com/entities/byd-co-ltd-h" target="_blank" data-smartkarma-citation="entities:20962:1" rel="noopener">BYD (1211 HK)</a>.</li>
</ul>


Inside is a recap of movements in the last week relating to the Shanghai and Shenzhen-Hong Kong Stock Connect facilities, broken down by company and industry. 
Overall, net inflow was ~US$1.1bn, split evenly (roughly) between Shanghai and Shenzhen. 
The largest inflows were into  China Mobile (941 HK) and CNOOC Ltd (883 HK). The largest outflows were in Kuaishou Technology (1024 HK) and BYD (1211 HK).


Shanghai/​Shenzhen Southbound Connect: Weekly Moves (27 May 2022)

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Thematic (Sector/Industry)

<ul>
<li>The NMPA has issued a draft regulation about rare diseases, which would have a profound impact. Investors are advised to follow this field as policy becomes more friendly.</li>
<li>After continuous corrections, many investors are wondering if the healthcare sector has reached bottom. We analyzed our thoughts and judgement.</li>
<li>Let's have a look at the lockdown in China from a different angle. The zero-COVID policy could make economic sense. The “travails” are significant for the coming economic crisis.</li>
</ul>


The NMPA has issued a draft regulation about rare diseases, which would have a profound impact. Investors are advised to follow this field as policy becomes more friendly.
After continuous corrections, many investors are wondering if the healthcare sector has reached bottom. We analyzed our thoughts and judgement.
Let's have a look at the lockdown in China from a different angle. The zero-COVID policy could make economic sense. The “travails” are significant for the coming economic crisis.


China Healthcare Weekly (May20)-Lockdown Impact on Macro Economy, Bottom Signal? Rare Disease Policy

<ul>
<li>We analyse the changes of A/H premium on 139 stocks over the last week. </li>
<li>Health care, consumer discretionary, and energy led the week on week A-H premium increase of 3.8ppt. </li>
<li>We highlight A-H premium increases in CICC, Great Wall Motor, and Cansino Biologics.</li>
</ul>


We analyse the changes of A/H premium on 139 stocks over the last week. 
Health care, consumer discretionary, and energy led the week on week A-H premium increase of 3.8ppt. 
We highlight A-H premium increases in CICC, Great Wall Motor, and Cansino Biologics.


A-H Premium Weekly: CICC, Great Wall Motor, Cansino

Equity Bottom-Up

<ul>
<li>We update our forecast on CanSino’s performance in 2022, which could be much lower than that in 2021 due to the concerns on commercialization outlook of COVID-19 vaccine and MCV2/MCV4.</li>
<li>However, due to strong R&amp;D and technology platforms, the value of CanSino's pipeline is higher and its products could become the ceiling of pricing power for other homogeneous competing products.</li>
<li>We still think CanSino has investment value in long term despite the headwinds in short term.The market value by May 6 of HK$18.1 billion (PE/TTM at 7.22) is also attractive.</li>
</ul>


We update our forecast on CanSino’s performance in 2022, which could be much lower than that in 2021 due to the concerns on commercialization outlook of COVID-19 vaccine and MCV2/MCV4.
However, due to strong R&amp;D and technology platforms, the value of CanSino's pipeline is higher and its products could become the ceiling of pricing power for other homogeneous competing products.
We still think CanSino has investment value in long term despite the headwinds in short term.The market value by May 6 of HK$18.1 billion (PE/TTM at 7.22) is also attractive.


CanSino Biologics (688185.CH/6185.HK) -Difficulties in 2022 Cannot Mask Long-Term Investment Value

China

CanSino Biologics Inc. develops and manufactures biological vaccine products. The Company discovers quadrivalence meningococcal conjugate, pneumococcal polysaccharide, and adenovirus vector-based tuberculosis vaccines for human use. CanSino Biologics serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

CanSino Biologics (6185 HK)

A-H Premium Weekly: Cansino, Great Wall Motor, Shandong Xinhua

We highlight weekly A-H premium changes of Cansino, Great Wall Motor, Shandong Xinhua, Xinhua Winshare, First Tractor, Joinn Lab.

Ke Yan, CFA, FRM

Shanghai/Shenzhen Southbound Connect: Weekly Moves (27 May 2022)

Overall, the total value increased US$1.8bn in the past week, with Shanghai accounting for US$1.9bn and Shenzhen (~US$0.2bn).

David Blennerhassett

China Healthcare Weekly (May20)-Lockdown Impact on Macro Economy, Bottom Signal? Rare Disease Policy

The lockdown could make economic sense, which is significant for coming economic crisis;We analyzed the bottom signal of biotech/CXO/medical...

Xinyao (Criss) Wang

A-H Premium Weekly: CICC, Great Wall Motor, Cansino

We highlight week-on-week A-H premium increases in CICC (3908 HK/601995 CH), Great Wall Motor (2333 HK/601623 CH), and Cansino Biologics (6185 HK...

Ke Yan, CFA, FRM

CanSino Biologics (688185.CH/6185.HK) -Difficulties in 2022 Cannot Mask Long-Term Investment Value

2022 will be difficult for CanSino. We lowered performance forecast.But due to strong R&D and technology platforms, the value of CanSino's pipeline...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

A-H Premium Weekly: Cansino, Great Wall Motor, Shandong Xinhua

We highlight weekly A-H premium changes of Cansino, Great Wall Motor, Shandong Xinhua, Xinhua Winshare, First Tractor, Joinn Lab.

Ke Yan, CFA, FRM

Shanghai/​Shenzhen Southbound Connect: Weekly Moves (27 May 2022)

Overall, the total value increased US$1.8bn in the past week, with Shanghai accounting for US$1.9bn and Shenzhen (~US$0.2bn).

David Blennerhassett

China Healthcare Weekly (May20)-Lockdown Impact on Macro Economy, Bottom Signal? Rare Disease Policy

The lockdown could make economic sense, which is significant for coming economic crisis;We analyzed the bottom signal of biotech/CXO/medical...

Xinyao (Criss) Wang

A-H Premium Weekly: CICC, Great Wall Motor, Cansino

We highlight week-on-week A-H premium increases in CICC (3908 HK/601995 CH), Great Wall Motor (2333 HK/601623 CH), and Cansino Biologics (6185 HK...

Ke Yan, CFA, FRM

CanSino Biologics (688185.CH/6185.HK) -Difficulties in 2022 Cannot Mask Long-Term Investment Value

2022 will be difficult for CanSino. We lowered performance forecast.But due to strong R&D and technology platforms, the value of CanSino's pipeline...

Xinyao (Criss) Wang

Shanghai/Shenzhen Southbound Connect: Weekly Moves (27 May 2022)